Abeona Therapeutics Inc.
$5.48
▲
5.24%
2026-04-21 05:01:00
www.abeonatherapeutics.com
NCM: ABEO
Explore Abeona Therapeutics Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$312.63 M
Current Price
$5.48
52W High / Low
$7.54 / $4
Stock P/E
4.39
Book Value
$2.89
Dividend Yield
—
ROCE
-47.08%
ROE
70.05%
Face Value
—
EPS
$1.01
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
226
Beta
1.21
Debt / Equity
15.68
Current Ratio
6.93
Quick Ratio
6.74
Forward P/E
20.46
Price / Sales
48.13
Enterprise Value
$113.67 M
EV / EBITDA
-1.31
EV / Revenue
19.53
Rating
None
Target Price
$19.57
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Net margin remains healthy.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Vivani Medical, Inc. | $1.51 | — | $127.82 M | — | -84.04% | -1.6% | $1.92 / $0.92 | $0.21 |
| 2. | eXoZymes, Inc. | $10.66 | — | $89.88 M | — | -220.6% | -1.33% | $18.4 / $7.08 | $0.4 |
| 3. | Phathom Pharmaceuticals, Inc. | $13.47 | — | $1.04 B | — | -125.87% | 63.97% | $18.31 / $2.21 | $-6.13 |
| 4. | Innoviva, Inc. | $23.92 | 6.53 | $1.77 B | — | 10.33% | 29.09% | $25.14 / $16.52 | $15.71 |
| 5. | CorMedix Inc. | $7.58 | 3.58 | $584.18 M | — | 23.03% | 66.56% | $17.43 / $6.13 | $5.11 |
| 6. | Creative Medical Technology Holdings, Inc. | $2.26 | — | $9.13 M | — | -81.64% | -86.47% | $6.25 / $1.5 | $2.03 |
| 7. | BridgeBio Pharma, Inc. | $74.02 | — | $14.41 B | — | -77.47% | 40.79% | $84.94 / $31.77 | $-10.71 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 5.42 M | 0 M | 0.4 M | 0 M | 0 M | — |
| Operating Profit | -22.91 M | -24.02 M | -22.79 M | -19.73 M | -16.67 M | — |
| Net Profit | -20.46 M | -5.16 M | 108.83 M | -12.03 M | -9.29 M | — |
| EPS in Rs | -0.36 | -0.09 | 1.91 | -0.21 | -0.16 | -0.63 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 5.82 M | 0 M | 3.5 M | 1.41 M |
| Operating Profit | -89.45 M | -64.21 M | -48.2 M | -45.26 M |
| Net Profit | 71.18 M | -63.73 M | -54.19 M | -39.7 M |
| EPS in Rs | 1.25 | -1.12 | -0.95 | -0.7 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 219.57 M | 108.93 M | 64 M | 64.21 M |
| Total Liabilities | 60.35 M | 64.9 M | 49.18 M | 37.45 M |
| Equity | 159.22 M | 44.03 M | 14.83 M | 26.76 M |
| Current Assets | 204.91 M | 100.85 M | 55.74 M | 53.1 M |
| Current Liabilities | 29.57 M | 16.59 M | 13.42 M | 7.78 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -76.33 M | -56.02 M | -37.01 M | -43.48 M |
| Investing CF | 105.03 M | -39.24 M | 0.21 M | -23.96 M |
| Financing CF | 26.04 M | 104.14 M | 37.06 M | 43.17 M |
| Free CF | -84.3 M | -58.46 M | -37.34 M | -43.61 M |
| Capex | -7.97 M | -2.45 M | -0.33 M | -0.13 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -100% | 147.52% | — | — |
| Earnings Growth % | -17.62% | -36.51% | — | — |
| Profit Margin % | — | -1548.23% | -2807.36% | — |
| Operating Margin % | — | -1377.14% | -3200.64% | — |
| Gross Margin % | — | 54.14% | 68.18% | — |
| EBITDA Margin % | — | -1444.91% | -2431.61% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2022-07-05 | 1:0.04 |